About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Early Diagnosis Of Childhood Cerebral ALD | Clinical Trials | Clareo Health

Back to clinical trial search

WITHDRAWNNCT02948062

Early Diagnosis Of Childhood Cerebral ALD

The goal of this single institution study is to evaluate boys with adrenoleukodystrophy (ALD) diagnosed early in life, and to prospectively monitor them to determine parameters that will facilitate ea...

Lead sponsor: Masonic Cancer Center, University of Minnesota•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Masonic Cancer Center, University of Minnesota

Age

1 - 5 years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Boys with confirmed adrenoleukodystrophy, as determined by very long chain fatty acid (VLCFA) analysis and/or genotyping. Genotyping is not necessary for diagnosis.
•Between 1 and 5 years of age, inclusive at the time of consent.
•Able to undergo a sedation
•English as primary language of the household, to maximize consistency of the neuropsychological/developmental testing.
•Voluntary written parental/guardian consent

Exclusion Criteria

•Evidence of cerebral disease at time of enrollment - patients over 3 years of age must have an MRI within 4 months of signing consent to confirm that there is no evidence of cerebral disease
•Inability or unwillingness to travel to the University of Minnesota once a year for the duration of the study
•Evidence of cerebral disease by standard T2/FLAIR MRI. If a subject develops cerebral ALD during the study, they will come off study, as it is anticipated that they would be considered for transplantation.

Related studies

RECRUITINGPhase 3

A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

NCT05819866 · Cerebral Adrenoleukodystrophy (cALD)

The Myelin Disorders Biorepository Project

NCT03047369 · Leukodystrophy, White Matter Disease, and more

RECRUITINGPhase 1

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

NCT02254863 · Adrenoleukodystrophy, Batten Disease, and more

Adrenoleukodystrophy National Registry Study

NCT03789721 · ALD (Adrenoleukodystrophy), Adrenoleukodystrophy, and more

Quality of Life in Women with X-linked Adrenoleukodystrophy

NCT04675749 · X-linked Adrenoleukodystrophy

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 6, 2018Terms

Trial snapshot

StatusWITHDRAWN

Phase—

Enrollment—

Start dateNov 2018

Last updatedJul 6, 2018

Condition

Adrenoleukodystrophy

Locations shown

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 6, 2018Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions